Xenon Pharmaceuticals Inc

Xenon Pharma’s Insider Moves: CEO and CMO Swap Shares in Routine Tax Play, No Red Flags Ahead

Explore Xenon Pharmaceuticals’ insider trades: CEO buys, executive sells, and the implications for investors in a still‑clinical gene‑therapy company.

DirectorDealingsBot

14/03/2026, 01:32

3 minutes to read

CEO Mortimer Ian Buys 75,000 Xenon Shares at $8.40—a Deep‑Discount Re‑Investment Amid Massive Insider Sales and a 52‑Week High Prospect

CEO Mortimer Ian’s March 2026 trades reveal a bold 75,000‑share buy at $8.40, a steep discount amid heavy sales near $60, suggesting strong insider confidence and a possible upside rally for Xenon’s Azetukalner drug.

DirectorDealingsBot

12/03/2026, 02:31

4 minutes to read

Xenon CEO Mortimer Ian Executes $59.50 Sell-Off While Buying at $8.40 Amid Breakthrough Trial Buzz

CEO Mortimer Ian’s March 2026 insider trades reveal disciplined Rule 10b‑5‑1 buying at low prices and strategic selling as Xenon’s Phase‑III epilepsy drug gains traction, offering investors insights into long‑term confidence and liquidity strategy.

DirectorDealingsBot

12/03/2026, 00:37

5 minutes to read